Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.
Ontology highlight
ABSTRACT: DNA vaccination exploits a relatively simple and flexible technique to generate an immune response against microbial and tumor-associated antigens (TAAs). Its effectiveness is enhanced by the application of an electrical shock in the area of plasmid injection (electroporation). In our studies we exploited a sophisticated electroporation device approved for clinical use (Cliniporator, IGEA, Carpi, Italy). As the target antigen is an additional factor that dramatically modulates the efficacy of a vaccine, we selected ErbB2 receptor as a target since it is an ideal oncoantigen. It is overexpressed on the cell membrane by several carcinomas for which it plays an essential role in driving their progression. Most oncoantigens are self-tolerated molecules. To circumvent immune tolerance we genera
SUBMITTER: Quaglino E
PROVIDER: S-EPMC3759195 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA